ArticlePloS one2026
Association between serum 25-hydroxyvitamin D levels and Early Vascular Aging in young and middle-aged adults.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) remains the leading cause of mortality and morbidity worldwide. Early vascular aging (EVA) is an independent predictor of cardiovascular risk in young and middle-aged adults. The plausible association between EVA and vitamin D warrants further investigation.
methodsThis study examined the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and EVA in young and middle-aged healthy adults.This cross-sectional study included 2047 eligible participants who underwent physical examinations at the Health Management Center of the Affiliated Hospital of Qingdao University between May 2023 and May 2025. Participants were categorized into EVA group (n = 687) and control group (n = 1360) based on brachial ankle pulse wave velocity (baPWV). Logistic regression and restricted cubic splines assessed the association between 25(OH)D and EVA, with an inflection point identified using two-piecewise linear regression. Subgroup analyses and interaction tests were conducted by age, sex, blood collection month, smoking status, alcohol drinking status, hypertension, diabetes, and body mass index (BMI).
resultsThe prevalence of EVA was 33.56%. Each 10 ng/mL increase in 25(OH)D was associated with a 19% decrease in the likelihood of EVA (OR = 0.81, 95% CI: 0.70-0.94, P = 0.008).Compared with Q1, Q4 had a significantly lower risk (OR = 0.55, 95% CI: 0.40-0.76, P < 0.001), while Q2 and Q3 did not differ (both P > 0.05). Restricted cubic spline analysis showed a nonlinear L-shaped association (P for non linearity = 0.015) with a threshold at 17.90 ng/mL: below this level, higher 25(OH)D was linked to a lower EVA risk (OR=0.90，95%CI: 0.85-0.96), whereas no significant association was observed above it. Subgroup analyses indicated a particularly significant inverse association between 25(OH)D levels and EVA in men and overweight/obese individuals. Significant interactions were observed for sex, BMI, and age (all P < 0.05), while interactions with other factors, such as blood collection month, hypertension, diabetes, smoking status, drinking status were not statistically significant.
conclusionThis study suggests an inverse association between 25(OH)D levels and EVA, with a more pronounced association possibly observed in men and individuals with overweight/obesity, and further indicates a threshold at 17.9 ng/mL below which this inverse association is significantly enhanced.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.